Home > Articles > Business & Management > Global Business

This chapter is from the book

Drugs for Smaller Patient Populations Drive Costs Even Higher

Annual sales of $1 billion are a strong incentive to focus on blockbusters and the large patient populations to which they can be marketed. The flipside is a disincentive to develop drugs for smaller markets. In 1983, in an effort to mitigate the problem, Congress enacted orphan drug legislation that gives market exclusivity to firms that introduce medicines with U.S. target populations of less than 200,000 and establishes difficult hurdles for potential competitors seeking to prove superiority of a new drug.8

With the orphan drug law, you see the beginnings of a premiumpricing model for new, smaller-market therapies. In a sense, it’s the opposite of the blockbuster model. When Genzyme Corporation developed Ceredase and Cerazyme to treat Gaucher’s disease, a rare genetic disorder of lipid metabolism that afflicts (among others) Jews of Eastern European descent, the potential U.S. patients numbered only in the thousands. Without the new drug, patients would likely die in childhood. But Genzyme found an enzyme extracted from placentas (later synthesized using recombinant DNA techniques) to be fully curative of the disorder. The market protection for its orphan drug made it possible for Genzyme to turn a profit, selling very small quantities of the drug at a very high price. In 2002, the price for an annual course of treatment was approximately $170,000, but few insured patients with a prescription drug benefit had any difficulty accessing the medicine or getting reimbursement. That was because the number of people with Gaucher’s disease is so small that the cost impact on insurers is minimal when averaged over all insured patients. Genzyme achieved early market success and substantial revenues.9 Other biotech firms addressed small “niche” or “boutique” drug markets. Biogen developed one of the first efficacious treatments for multiple sclerosis (MS), a neuromuscular degenerative disease of autoimmune origin that afflicts only around 400,000 people in the United States. (In the world of pharmaceuticals, you’ll often hear about “efficacy” and “effectiveness.” In this context, efficacy is the ability to produce a specifically desired effect, and is usually demonstrated in clinical trials. Effectiveness is demonstrated in practice.) Immunex developed a new treatment for rheumatoid arthritis (RA), a condition affecting only some 300,000 U.S. patients.10 Like Genzyme’s new drug, these drugs need to be taken every day for the rest of a patient’s life, or until something better comes along—at a substantial cost.11

These examples set the new premium-pricing model for new, smaller-market drug therapies. It was a model that fit for many drug introductions that followed, including for Crohn’s disease, a progressive gastrointestinal disorder of autoimmune origin; allergies and asthma; psoriasis; fungus infections afflicting immunocompromised patients; and the new, targeted cancer therapies. The model applied even to a stalwart class of drugs: antibacterial antibiotics. There’s always a need for new antibiotic medications because the evolution of disease-causing organisms leads to drug resistance. New antibiotics are typically reserved by doctors for patients who aren’t responding to any of the older drugs, and so the market size and revenues are limited. But these antibiotic drugs are sold at a premium pricing level, which is exactly how the few totally new antibiotics introduced in the past two decades have entered the market. The model also applies to the major advances achieved in the treatment of HIV/AIDS, which were once nearly always fatal but are now treatable, chronic conditions. The high prices, though, limit access in the developing world, where HIV/AIDS is far more prevalent.

The latest wave of scientific advances, which facilitates new approaches to select therapies for ill patients, promises to raise even greater cost challenges. The sequencing of the human genome gives scientists detailed information about the functions of a number of genes, and drugs are being developed to correct, ameliorate, or otherwise address genetic defects that lead to disease. And in theory, it’s even possible to test—with high confidence—which patients with a given defect will benefit from the treatment.

How much higher will drug prices go with these new therapies? They come at a very high cost, according to a Business Week article reviewing new cancer therapies, titled “Going Broke to Stay Alive.” Among other drugs, the story discusses Gleevec, a Novartis drug that treats two forms of cancer associated with a single genetic defect, and Genentech’s Herceptin, which treats a hereditary form of breast cancer that afflicts some 15–25 percent of all patients who develop the disease. Gleevec specifically targets a genetic defect and is highly efficacious in the target group of cancer patients and responsible for significant increases in patient survival, but does nothing for patients with other forms of cancer who do not have the genetic defect. Herceptin has an antibody that targets only patients whose genomes include the BRCA-1 gene; in other words, it interferes with the progression of the cancer. A diagnostic test predicts with high confidence which patients are candidates for the therapy. This drug also increases a patient’s chances for survival compared to earlier therapeutic approaches.12

Gleevec costs $2,200 a month and can be taken indefinitely, while Herceptin runs $3,200 a month, with an additional expense of $100 a pill for an anti-nausea drug to relieve side effects. Hence the article’s title. Gleevec’s annual revenues were $2.2 billion, exceeding the blockbuster threshold, while Herceptin’s revenues were near $1 billion a year between 1998 and 2005.13

Targeted therapies aimed at a specific patient’s unique characteristics will only become more common. But the costs to patients and payers (insurance companies and health plans) are becoming more and more prohibitive. Even the director of the National Institutes of Health acknowledges that the overall cost society pays for drugs cannot be reduced unless people stop taking drugs from which they don’t realize much (or any) benefit.

How will the marketplace for pharmaceuticals respond to monumental scientific breakthroughs and the new model for premium pricing for smaller target populations?14 To what degree do we have to fail to capitalize on scientific and technological advances before policy makers have had enough? Which therapies that might work, but never get developed, have to fall by the wayside before people demand that our broken system be fixed? Are you willing to watch your loved ones suffer while business considerations get in the way of taking the next steps to get needed medicines?

If prices keep rising, many more people will lose access to needed medicines. If the drug companies don’t take in billions in profits, they claim they’ll have to put the brakes on innovation. The incentives are all askew and society’s interests get short shrift in the fallout. Business decisions encroach on medical advances—a situation none of us can afford.

To understand just how big a deal this is, let’s explore one scientific breakthrough that is suffering from this condition.

InformIT Promotional Mailings & Special Offers

I would like to receive exclusive offers and hear about products from InformIT and its family of brands. I can unsubscribe at any time.


Pearson Education, Inc., 221 River Street, Hoboken, New Jersey 07030, (Pearson) presents this site to provide information about products and services that can be purchased through this site.

This privacy notice provides an overview of our commitment to privacy and describes how we collect, protect, use and share personal information collected through this site. Please note that other Pearson websites and online products and services have their own separate privacy policies.

Collection and Use of Information

To conduct business and deliver products and services, Pearson collects and uses personal information in several ways in connection with this site, including:

Questions and Inquiries

For inquiries and questions, we collect the inquiry or question, together with name, contact details (email address, phone number and mailing address) and any other additional information voluntarily submitted to us through a Contact Us form or an email. We use this information to address the inquiry and respond to the question.

Online Store

For orders and purchases placed through our online store on this site, we collect order details, name, institution name and address (if applicable), email address, phone number, shipping and billing addresses, credit/debit card information, shipping options and any instructions. We use this information to complete transactions, fulfill orders, communicate with individuals placing orders or visiting the online store, and for related purposes.


Pearson may offer opportunities to provide feedback or participate in surveys, including surveys evaluating Pearson products, services or sites. Participation is voluntary. Pearson collects information requested in the survey questions and uses the information to evaluate, support, maintain and improve products, services or sites, develop new products and services, conduct educational research and for other purposes specified in the survey.

Contests and Drawings

Occasionally, we may sponsor a contest or drawing. Participation is optional. Pearson collects name, contact information and other information specified on the entry form for the contest or drawing to conduct the contest or drawing. Pearson may collect additional personal information from the winners of a contest or drawing in order to award the prize and for tax reporting purposes, as required by law.


If you have elected to receive email newsletters or promotional mailings and special offers but want to unsubscribe, simply email information@informit.com.

Service Announcements

On rare occasions it is necessary to send out a strictly service related announcement. For instance, if our service is temporarily suspended for maintenance we might send users an email. Generally, users may not opt-out of these communications, though they can deactivate their account information. However, these communications are not promotional in nature.

Customer Service

We communicate with users on a regular basis to provide requested services and in regard to issues relating to their account we reply via email or phone in accordance with the users' wishes when a user submits their information through our Contact Us form.

Other Collection and Use of Information

Application and System Logs

Pearson automatically collects log data to help ensure the delivery, availability and security of this site. Log data may include technical information about how a user or visitor connected to this site, such as browser type, type of computer/device, operating system, internet service provider and IP address. We use this information for support purposes and to monitor the health of the site, identify problems, improve service, detect unauthorized access and fraudulent activity, prevent and respond to security incidents and appropriately scale computing resources.

Web Analytics

Pearson may use third party web trend analytical services, including Google Analytics, to collect visitor information, such as IP addresses, browser types, referring pages, pages visited and time spent on a particular site. While these analytical services collect and report information on an anonymous basis, they may use cookies to gather web trend information. The information gathered may enable Pearson (but not the third party web trend services) to link information with application and system log data. Pearson uses this information for system administration and to identify problems, improve service, detect unauthorized access and fraudulent activity, prevent and respond to security incidents, appropriately scale computing resources and otherwise support and deliver this site and its services.

Cookies and Related Technologies

This site uses cookies and similar technologies to personalize content, measure traffic patterns, control security, track use and access of information on this site, and provide interest-based messages and advertising. Users can manage and block the use of cookies through their browser. Disabling or blocking certain cookies may limit the functionality of this site.

Do Not Track

This site currently does not respond to Do Not Track signals.


Pearson uses appropriate physical, administrative and technical security measures to protect personal information from unauthorized access, use and disclosure.


This site is not directed to children under the age of 13.


Pearson may send or direct marketing communications to users, provided that

  • Pearson will not use personal information collected or processed as a K-12 school service provider for the purpose of directed or targeted advertising.
  • Such marketing is consistent with applicable law and Pearson's legal obligations.
  • Pearson will not knowingly direct or send marketing communications to an individual who has expressed a preference not to receive marketing.
  • Where required by applicable law, express or implied consent to marketing exists and has not been withdrawn.

Pearson may provide personal information to a third party service provider on a restricted basis to provide marketing solely on behalf of Pearson or an affiliate or customer for whom Pearson is a service provider. Marketing preferences may be changed at any time.

Correcting/Updating Personal Information

If a user's personally identifiable information changes (such as your postal address or email address), we provide a way to correct or update that user's personal data provided to us. This can be done on the Account page. If a user no longer desires our service and desires to delete his or her account, please contact us at customer-service@informit.com and we will process the deletion of a user's account.


Users can always make an informed choice as to whether they should proceed with certain services offered by InformIT. If you choose to remove yourself from our mailing list(s) simply visit the following page and uncheck any communication you no longer want to receive: www.informit.com/u.aspx.

Sale of Personal Information

Pearson does not rent or sell personal information in exchange for any payment of money.

While Pearson does not sell personal information, as defined in Nevada law, Nevada residents may email a request for no sale of their personal information to NevadaDesignatedRequest@pearson.com.

Supplemental Privacy Statement for California Residents

California residents should read our Supplemental privacy statement for California residents in conjunction with this Privacy Notice. The Supplemental privacy statement for California residents explains Pearson's commitment to comply with California law and applies to personal information of California residents collected in connection with this site and the Services.

Sharing and Disclosure

Pearson may disclose personal information, as follows:

  • As required by law.
  • With the consent of the individual (or their parent, if the individual is a minor)
  • In response to a subpoena, court order or legal process, to the extent permitted or required by law
  • To protect the security and safety of individuals, data, assets and systems, consistent with applicable law
  • In connection the sale, joint venture or other transfer of some or all of its company or assets, subject to the provisions of this Privacy Notice
  • To investigate or address actual or suspected fraud or other illegal activities
  • To exercise its legal rights, including enforcement of the Terms of Use for this site or another contract
  • To affiliated Pearson companies and other companies and organizations who perform work for Pearson and are obligated to protect the privacy of personal information consistent with this Privacy Notice
  • To a school, organization, company or government agency, where Pearson collects or processes the personal information in a school setting or on behalf of such organization, company or government agency.


This web site contains links to other sites. Please be aware that we are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of each and every web site that collects Personal Information. This privacy statement applies solely to information collected by this web site.

Requests and Contact

Please contact us about this Privacy Notice or if you have any requests or questions relating to the privacy of your personal information.

Changes to this Privacy Notice

We may revise this Privacy Notice through an updated posting. We will identify the effective date of the revision in the posting. Often, updates are made to provide greater clarity or to comply with changes in regulatory requirements. If the updates involve material changes to the collection, protection, use or disclosure of Personal Information, Pearson will provide notice of the change through a conspicuous notice on this site or other appropriate way. Continued use of the site after the effective date of a posted revision evidences acceptance. Please contact us if you have questions or concerns about the Privacy Notice or any objection to any revisions.

Last Update: November 17, 2020